- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03320525
Pharmacokinetic Profile of T-ChOS™ in Subjects With Advanced Solid Tumors (CHITIN) (CHITIN)
A Single Center, Open-Label, Phase 1 Study to Evaluate the Pharmacokinetic Profile of T-ChOS™ in Subjects With Advanced Solid Tumors (CHITIN)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
YKL-40 (also named chitinase 3 like-1 protein, CHI3L1), is a member of the mammalian chitinase like proteins and is a highly conserved glycoprotein. YKL-40 is produced by cancer cells and macrophages and promotes cancer progression by activating inflammation and inhibiting tumor angiogenesis. Thus, YKL-40 could be a new therapeutic target for patients with cancer.
T-ChOS™ is a technical name for a food supplement product that is marketed in Iceland under the name Benecta™. T-ChOS is manufactured using shellfish derived chitin as a raw material and is produced by Genis in Iceland. It is a blend of chitooligosaccharides that are hetero-complexes of N-acetyl-glucosamine and D-glucosamine. T-ChOS chitooligosaccharides have been specially selected to have high bioactivity in inflammatory models and strong binding affinity to YKL-40. Chitooligosaccharide induced blockade of YKL-40 signalling pathways may represents a promising approach. Pharmacokinetic profile of the T-ChOS in patients with advanced solid malignancies is not available.
Safety and tolerability data will be collected to expand the safety/tolerability database for patients with advanced solid malignancies treated with oral T-ChOS. Patients will be allowed to receive T-ChOS on a continuous basis and therefore have the possibility to gain clinical benefit, if any. Safety and tolerability data collected after pharmacokinetic part of the study will be also added to the safety database for patients with advanced solid malignancies treated with oral T-ChOS.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Herlev, Denmark, 2730
- Herlev & Gentofte University Hospital, Denmark
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
INCLUSION CRITERIA:
- Signed written Informed Consent
- Male or females aged 18 to 75 years at the time of signing the informed consent form (ICF)
- Patients must have histological confirmed malignancy (solid tumor) that is metastatic or unresectable and for which standard curative or palliative therapies do not exist or are no longer effective
- Understand and voluntarily sign an ICF prior to any study related assessments or procedures being conducted
- Performance status 0-1 (ECOG)
- Life expectancy ≥ 3 months
- Elevated blood YKL-40 > 40 μg/L, assessed within 28 days prior to the start of the study
Hematopoietic
- Absolute neutrophil count (ANC) ≥ 1.5 x 10⁹/L
- Platelet count ≥ 100 x 10⁹/L
- Haemoglobin ≥ 5.6 mmol/L
Hepatic
- Serum bilirubin < 1.5 x upper limit of normal (ULN)
- AST/ALT < 2.5 x ULN (< 5 x ULN with known liver metastasis)
Renal
- Acceptable renal function with a creatinine clearance ≥ 50 mL/min/ (e.g., using the Cockroft-Gault formula)
Cardiovascular
- No severe or uncontrolled cardiac condition
Pulmonary
- No severe or uncontrolled pulmonary condition
Immunologic
- No known or suspected allergy to the investigational product
Gastrointestinal
- No chronic enteropathy (e.g. active inflammatory bowel disease, extensive intestinal resection or chronic diarrhea)
- No bowel obstruction or sub-obstruction
- No prior history of intestinal malabsorption
- Patients have to be able to swallow normally and have to be willing to comply with the intake of capsules
Others
- No psychiatric condition that would preclude study participation
- No co-existing active infection requiring antibiotics or any co-existing medical conditions likely to interfere with study procedures
- No other condition that will preclude study participation
- A negative pregnancy test for women of childbearing potential. For men and women of child-producing potential, the use of effective contraceptives methods during the study and at least 3 months after discontinuations of the investigational product is required. The following contraceptive methods are regarded as effective: intrauterine devices, hormonal contraceptives (contraceptive pills, implants, transdermal patches, hormonal vaginal devices or injections with prolonged release). Sterilised or infertile patients are exempt from the requirement to use contraception. In order to be considered sterilised or infertile, patients must generally have undergone surgical sterilisation (vasectomy/bilateral tubectomy, hysterectomy or bilateral ovariectomy) or be postmenopausal defined as 12 months or more with no menses prior to enrolment
- Not pregnant or nursing
- Be able to adhere to the study visit schedule and other protocol requirements
EXCLUSION CRITERIA:
- Simultaneous participation in any other study involving investigational drugs or having participated in a study within 2 weeks prior to start of study treatment
- Current use of anticoagulation therapy such as heparins both unfractionated and low molecular weighted
- Symptomatic brain metastases
- Intake of any prohibited concomitant medication
Prior and Concurrent Therapy at least 2 weeks prior to 1st dosing:
- Biologic/immunotherapy
- Chemotherapy
- Radiotherapy
- Major or laparoscopic surgery
- Other concurrent anticancer therapy
- Corticosteroids or other immunosuppressive medications. Inhaled or topical steroids are permitted.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Experimental
The active substance used in the T-ChOS capsule formulation is a chitooligosaccharide blend.
|
T-ChOS 600 mg (two capsules, each 300 mg) daily in the morning 30 minutes before food.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pharmacokinetic parameters will be assessed for T-ChOS
Time Frame: Approximately up to 12 months
|
• time to reach maximum plasma concentration (tmax)
|
Approximately up to 12 months
|
Pharmacokinetic parameters will be assessed for T-ChOS
Time Frame: Approximately up to 12 months
|
• area under the plasma concentration-time curve from zero to the last measurable time point (AUC0-t)
|
Approximately up to 12 months
|
Pharmacokinetic parameters will be assessed for T-ChOS
Time Frame: Approximately up to 12 months
|
• area under the plasma concentration-time curve from zero to infinity (AUC)
|
Approximately up to 12 months
|
Pharmacokinetic parameters will be assessed for T-ChOS
Time Frame: Approximately up to 12 months
|
• apparent plasma clearance following oral administration (CL/F)
|
Approximately up to 12 months
|
Pharmacokinetic parameters will be assessed for T-ChOS
Time Frame: Approximately up to 12 months
|
• terminal half-life (t½)
|
Approximately up to 12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
Time Frame: Approximately up to 18 months.
|
Safety and tolerability of the treatment regimens assessed by a summary of adverse events and clinical laboratory assessments.
|
Approximately up to 18 months.
|
Overall response rate (ORR)
Time Frame: Approximately up to 18 months.
|
ORR = complete response + partial response, according to RECIST 1.1
|
Approximately up to 18 months.
|
Disease control rate (DCR)
Time Frame: Approximately up to 18 months.
|
DCR = complete response + partial response + stable disease, according to RECIST 1.1
|
Approximately up to 18 months.
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Serum YKL-40
Time Frame: Approximately up to 18 months.
|
Serum YKL-40 during and following 4 weeks of treatment with T-ChOS
|
Approximately up to 18 months.
|
Serum CRP
Time Frame: Approximately up to 18 months.
|
Serum CRP during and following 4 weeks of treatment with T-ChOS
|
Approximately up to 18 months.
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- AA1602
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced Solid Tumors
-
AmgenCompletedCancer | Advanced Solid Tumors | Solid Tumors | Tumors | Advanced MalignancyUnited States, Australia
-
NantCell, Inc.CompletedQUILT-2.016: Study of AMG 479 With Biologics or Chemotherapy for Subjects With Advanced Solid TumorsCancer | Advanced Solid Tumors | Solid Tumors | Tumors | Advanced Malignancy
-
Incyte CorporationRecruitingA Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid TumorsAdvanced Solid Tumors | Solid Tumors | Metastatic Solid TumorsUnited States, Spain, United Kingdom, France, Italy, Denmark, Switzerland
-
Hoffmann-La RocheCompletedSolid Tumors, Advanced Solid TumorsUnited States
-
Esperance Pharmaceuticals IncCompletedAdvanced Solid Tumors | Solid TumorsUnited States
-
Millennium Pharmaceuticals, Inc.CompletedAdvanced Solid Tumors, Neoplasms, Advanced SolidHungary
-
Incyte Biosciences Japan GKCompletedAdvanced Solid Tumors | Metastatic Solid TumorsJapan
-
Memorial Sloan Kettering Cancer CenterKyowa Hakko Kirin Pharma, Inc.CompletedAdvanced Solid Tumors | Metastatic Solid TumorsUnited States
-
Bristol-Myers SquibbCompletedAdvanced Solid Tumors | Metastatic Solid TumorsKorea, Republic of, Canada, Australia
-
Vividion Therapeutics, Inc.RecruitingAdvanced Solid Tumors | Advanced Hematologic TumorsUnited States, Australia
Clinical Trials on T-ChOS
-
Herlev HospitalGENISTerminated
-
Biotronik SE & Co. KGCompletedHeart Failure | BradycardiaDenmark, Hong Kong, Austria, Germany, Belgium
-
University of California, BerkeleyUniversity of Nevada, Reno; World Bank; L'Office National de Nutrition, MadagascarRecruitingEarly Childhood DevelopmentMadagascar
-
Biotronik SE & Co. KGCompletedVentricular Fibrillation | Ventricular TachycardiaGermany, Czech Republic
-
University of South FloridaNational Cancer Institute (NCI)RecruitingCancer | Obesity, Childhood | SurvivorshipUnited States
-
Hebei Senlang Biotechnology Inc., Ltd.RecruitingLymphoma | Multiple Myeloma | Acute Lymphoblastic LeukemiaChina
-
The First Affiliated Hospital of Soochow UniversityRecruitingRelapsed/Refractory B-cell Non-Hodgkin's LymphomaChina
-
Yooyoung Pharmaceutical Co., Ltd.CompletedDyslipidemiasKorea, Republic of
-
City of Hope Medical CenterNational Cancer Institute (NCI); California Institute for Regenerative Medicine...RecruitingBreast Cancer | HER2-positive Breast Cancer | Malignant Neoplasm | Metastatic Malignant Neoplasm in the Brain | Metastatic Malignant Neoplasm in the LeptomeningesUnited States
-
Everett MeyerNational Heart, Lung, and Blood Institute (NHLBI); National Institutes of Health...CompletedLymphoma, Non-Hodgkin | Acute Myeloid Leukemia | Acute Leukemia | Acute Myelogenous Leukemia | Chronic Myelogenous Leukemia | Myelodysplastic Syndromes (MDS) | Acute Lymphoblastic Leukemia (ALL) | Myeloid Leukemia, Chronic | Myeloproliferative SyndromeUnited States